Aeterna Zentaris (NASDAQ:AEZS) Now Covered by

Equities researchers at started coverage on shares of Aeterna Zentaris (NASDAQ:AEZSGet Rating) (TSE:AEZ) in a research note issued to investors on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Stock Down 1.3 %

NASDAQ AEZS opened at $2.72 on Friday. The company has a market capitalization of $13.19 million, a P/E ratio of -1.06 and a beta of 1.43. Aeterna Zentaris has a 12-month low of $2.54 and a 12-month high of $9.75. The firm has a 50-day moving average price of $3.47 and a two-hundred day moving average price of $3.70.

Aeterna Zentaris Company Profile

(Get Rating)

Æterna Zentaris, Inc operates as a specialty biopharmaceutical company, which engages in the development of therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.

Recommended Stories

Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with's FREE daily email newsletter.